Business Update12 Jun 2026, 01:30 pm
Concord Biotech API Facility Clears ANVISA Inspection
AI Summary
Concord Biotech announced the successful completion of an ANVISA (Brazilian Health Regulatory Agency) inspection at its API manufacturing facility in Limbasi. The inspection, conducted from June 8-12, 2026, is a significant milestone for the company's global expansion. This successful audit reinforces Concord Biotech's commitment to high quality and regulatory standards, strengthens its global manufacturing and regulatory presence, and enhances its access to the Brazilian pharmaceutical market, potentially broadening the reach of its APIs globally.
Key Highlights
- ANVISA inspection at API facility successfully completed.
- Inspection reinforces commitment to quality and regulatory standards.
- Enhances global manufacturing footprint and market access.
- Strengthens position in key global pharmaceutical markets.
Price Impact
More from CONCORDBIO